Guidance for Industry
fda.gov · 7,223 words · saved by 1 readers
N/A
Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Oncology Center of Excellence (OCE) Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) October 2022 Clinical/Medical Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment Guidance for Industry…
saved by
related reading
- Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangementsnature.com
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemianature.com
- RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia - PubMedpubmed.ncbi.nlm.nih.gov
- The current state of the art and future trends in RAS-targeted cancer therapiesnature.com
- Initial treatment of acute promyelocytic leukemia in adultsuptodate.com
- America Must Address Early Clinical Developmentfda.gov
- Federal Register :: Platform Technology Designation Program; Draft Guidance for Industry; Availability; Agency Information Collection Activities; Proposed Collection; Comment Requestfederalregister.gov
- FDA Announces Major Steps to Implement Real-Time Clinical Trials | FDAfda.gov
- Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adultsuptodate.com
- Hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes in children and adolescentsuptodate.com
- RNA Interference–Based Therapy and Its Delivery Systemsncbi.nlm.nih.gov
- Immunotherapy in pediatric malignancies: current status and future perspectives - PMCncbi.nlm.nih.gov